Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies

Christine Mack; Kevin Laugero; Que Liu; Carolyn Jodka; Andrew Young; David Parkes

doi:10.1002/ddr.20121

Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies

Christine Mack, Kevin Laugero, Que Liu, Carolyn Jodka, Andrew Young, David Parkes

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.

Original language	English (US)
Pages (from-to)	553-558
Number of pages	6
Journal	Drug Development Research
Volume	67
Issue number	7
DOIs	https://doi.org/10.1002/ddr.20121
State	Published - Jul 2006
Externally published	Yes

Keywords

Exenatide
GLP-1
Heart failure
Hypertension
Obesity

ASJC Scopus subject areas

Drug Discovery
Organic Chemistry
Pharmacology

Access to Document

10.1002/ddr.20121

Fingerprint Dive into the research topics of 'Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies'. Together they form a unique fingerprint.

Cite this

@article{ae318c4fe25a4c89afb5fd449483de9a,

title = "Therapeutic applications of incretin mimetics for metabolic diseases: Preclinical studies",

abstract = "Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.",

keywords = "Exenatide, GLP-1, Heart failure, Hypertension, Obesity",

author = "Christine Mack and Kevin Laugero and Que Liu and Carolyn Jodka and Andrew Young and David Parkes",

year = "2006",

month = jul,

doi = "10.1002/ddr.20121",

language = "English (US)",

volume = "67",

pages = "553--558",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Therapeutic applications of incretin mimetics for metabolic diseases

T2 - Preclinical studies

AU - Mack, Christine

AU - Laugero, Kevin

AU - Liu, Que

AU - Jodka, Carolyn

AU - Young, Andrew

AU - Parkes, David

PY - 2006/7

Y1 - 2006/7

N2 - Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.

AB - Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in all species studied. GLP-1 and exenatide have also been shown to modulate cardiovascular function in both animal and human studies. This overview examines the metabolic effects of exenatide beyond its antidiabetic actions, and will focus on studies with respect to obesity, hypertension, and cardiac dysfunction in preclinical models of diet-induced obesity, metabolic syndrome, and chronic heart failure.

KW - Exenatide

KW - GLP-1

KW - Heart failure

KW - Hypertension

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=33845192364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845192364&partnerID=8YFLogxK

U2 - 10.1002/ddr.20121

DO - 10.1002/ddr.20121

M3 - Article

AN - SCOPUS:33845192364

VL - 67

SP - 553

EP - 558

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 7

ER -